N
Neal L. Benowitz
Researcher at University of California, San Francisco
Publications - 825
Citations - 66786
Neal L. Benowitz is an academic researcher from University of California, San Francisco. The author has contributed to research in topics: Nicotine & Cotinine. The author has an hindex of 126, co-authored 792 publications receiving 60658 citations. Previous affiliations of Neal L. Benowitz include Shaare Zedek Medical Center & University College London.
Papers
More filters
Journal ArticleDOI
Nicotine effects on eicosanoid formation and hemostatic function: Comparison of transdermal nicotine and cigarette smoking ☆ ☆☆
Neal L. Benowitz,Garret A. Fitzgerald,Garret A. Fitzgerald,Margaret Wilson,Margaret Wilson,Qi Zhang,Qi Zhang +6 more
TL;DR: Transdermal nicotine has less effect on platelet activation and catecholamine release than does cigarette smoking, and its use in smoking cessation treatment of patients with coronary heart disease is likely to be safer than cigarette smoking.
Journal ArticleDOI
Influence of nicotine on cardiovascular and hormonal effects of cigarette smoking.
TL;DR: The amount of nicotine consumed when assessed over the whole day has little influence on magnitude of cardiovascular responses to cigarette smoking, and changing nicotine content per se may not alter the risk of sudden adverse cardiac events associated with cigarette smoking.
Journal ArticleDOI
Determination of the Nicotine Metabolites Cotinine and Trans-3′-Hydroxycotinine in Biologic fluids of Smokers and Non-Smokers using Liquid Chromatography - Tandem Mass Spectrometry: Biomarkers for Tobacco Smoke Exposure and for Phenotyping Cytochrome P450 2A6 Activity
TL;DR: A highly sensitive liquid chromatography-tandem mass spectrometry method for determination of the nicotine metabolites cotinine and trans-3'-hydroxycotinine in human plasma, urine, and saliva is described.
Journal ArticleDOI
The functional mu opioid receptor (OPRM1) Asn40Asp variant predicts short-term response to nicotine replacement therapy in a clinical trial
Caryn Lerman,E P Wileyto,Freda Patterson,Margaret Rukstalis,Janet Audrain-McGovern,Stephanie Restine,Peter G. Shields,Vyga Kaufmann,David T. Redden,Neal L. Benowitz,Wade H. Berrettini +10 more
TL;DR: Smokers who carry the OPRM1 Asp40 variant are likely to have a favorable response to TN and may benefit from extended therapy with the 21 mg dose.
Journal ArticleDOI
Determinants of nicotine intake while chewing nicotine polacrilex gum
TL;DR: The systemic dose of nicotine was less than expected based on analysis of nicotine in the chewed gum, and swallowing of nicotine appears to be an important determinant of systemic nicotine intake.